Abstract
Purpose
To create a preoperative prediction model for estimating the risk of non-organ-confined (pT3-4 or pN+) bladder urothelial cancer (NOC–BUC) in patients with clinically OC–BUC (cT1-2N0M0).
Methods
The study involved 248 consecutive patients who had undergone radical surgery for clinically OC–BUC at a tertiary cancer center between 2003 and 2011. Logistic regression analysis was used to develop a prediction model for estimating the risk of pathological NOC disease. Prespecified predictors included age, gender, recurrent frequency, tumor size and number, hydronephrosis, and pathological characteristics at transurethral resection (T-stage, tumor grade, lymphovascular invasion (LVI), and carcinoma in situ). Discrimination ability was measured by the area under the receiver operating characteristic curve (AUC).
Results
Overall, 39.1 % of the patients with clinically OC–BUC had NOC disease at the time of radical surgery. In multivariate analysis, recurrent frequency, tumor size, hydronephrosis, and three pathological features at transurethral resection (T-stage, tumor grade, and LVI) were significantly associated with disease extent. The final prediction model included seven variables after backward elimination and achieved a bootstrap-corrected AUC of 0.79. Internal validation showed good calibration and clinical usefulness of the nomogram.
Conclusions
Based on readily available clinicopathological parameters, we developed a nomogram for predicting NOC tumor in clinically OC–BUC. Despite reasonable performance in internal validation, the prediction model should be assessed in external dataset before applied in clinical setting.
Similar content being viewed by others
Abbreviations
- NOC–BUC:
-
Non-organ-confined bladder urothelial cancer
- OC–BUC:
-
Organ-confined bladder urothelial cancer
- LVI:
-
Lymphovascular invasion
- AUC:
-
Area under curve
- RC:
-
Radical cystectomy
- PLND:
-
Pelvic lymph node dissection
- CT:
-
Computed tomography
- MRI:
-
Magnetic resonance imaging
- TUR:
-
Transurethral resection
- CIS:
-
Carcinoma in situ
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. doi:10.3322/caac.20107
Jacobs BL, Lee CT, Montie JE (2010) Bladder cancer in 2010: how far have we come? CA Cancer J Clin 60(4):244–272. doi:10.3322/caac.20077
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19(3):666–675
Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, Studer UE (2003) Radical cystectomy for bladder cancer today–a homogeneous series without neoadjuvant therapy. J Clin Oncol 21(4):690–696
Manoharan M, Ayyathurai R, Soloway MS (2009) Radical cystectomy for urothelial carcinoma of the bladder: an analysis of perioperative and survival outcome. BJU Int 104(9):1227–1232. doi:10.1111/j.1464-410X.2009.08625.x
Takahashi A, Tsukamoto T, Tobisu K, Shinohara N, Sato K, Tomita Y, Komatsubara S, Nishizawa O, Igarashi T, Fujimoto H, Nakazawa H, Komatsu H, Sugimura Y, Ono Y, Kuroda M, Ogawa O, Hirao Y, Hayashi T, Tsushima T, Kakehi Y, Arai Y, Ueda S, Nakagawa M (2004) Radical cystectomy for invasive bladder cancer: results of multi-institutional pooled analysis. Jpn J Clin Oncol 34(1):14–19
Winquist E, Kirchner TS, Segal R, Chin J, Lukka H (2004) Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 171(2 Pt 1):561–569. doi:10.1097/01.ju.0000090967.08622.33
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48(2):202–205. doi:10.1016/j.eururo.2005.04.006 (discussion 205–206)
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New Engl J Med 349(9):859–866. doi:10.1056/NEJMoa022148
Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP (2004) Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol 171(5):1830–1834. doi:10.1097/01.ju.0000121604.58067.95
Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR, Catton CN, McLean M, Moore M, Tannock IF, Gospodarowicz MK (2007) Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 25(4):303–309. doi:10.1016/j.urolonc.2006.09.015
Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20(14):3061–3071
Cowan NC, Crew JP (2010) Imaging bladder cancer. Curr Opin Urol 20(5):409–413. doi:10.1097/MOU.0b013e32833cbcb9
Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Dinney CP (2011) Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 107(6):898–904. doi:10.1111/j.1464-410X.2010.09628.x
Karakiewicz PI, Shariat SF, Palapattu GS, Perrotte P, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg M, Lerner SP (2006) Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 50(6):1254–1260. doi:10.1016/j.eururo.2006.06.010 (discussion 1261–1252)
May M, Burger M, Brookman-May S, Otto W, Peter J, Rud O, Fritsche HM, Bolenz C, Trojan L, Herrmann E, Michel MS, Wulfing C, Moritz R, Tiemann A, Muller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Gilfrich C, Hofner T, Hohenfellner M, Haferkamp A, Roigas J, Bretschneider-Ehrenberg P, Muller O, Zacharias M, Gunia S, Bastian PJ (2011) Validation of pre-cystectomy nomograms for the prediction of locally advanced urothelial bladder cancer in a multicentre study: are we able to adequately predict locally advanced tumour stages before surgery? Der Urologe Ausg A 50(6):706–713. doi:10.1007/s00120-011-2506-x
Bostrom PJ, van Rhijn BWG, Fleshner N, Finelli A, Jewett M, Thoms J, Hanna S, Kuk C, Zlotta AR (2010) Staging and staging errors in bladder cancer. Eur Urol Suppl 9(1):2–9. doi:10.1016/j.eursup.2010.01.005
Niegisch G, Albers P (2011) Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer? Curr Opin Urol 21(5):434–439. doi:10.1097/MOU.0b013e328349582e
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, Rouprêt M (2011) EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59(6):997–1008. doi:10.1016/j.eururo.2011.03.017
Algaba F (2006) Lymphovascular invasion as a prognostic tool for advanced bladder cancer. Curr Opin Urol 16(5):367–371. doi:10.1097/01.mou.0000240311.08701.55
Sobin LH, Gospodariwicz M, Wittekind C (2009) TNM classification of malignant tumors. UICC International Union Against Cancer. 7 edn. Wiley, London
Mostofi FK, Sobin LH, Torloni H (1973) Histological typing of urinary bladder tumours. World Health Organization, Geneva
Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):465–466. doi:10.1016/j.eururo.2005.12.031 (discussion 475–467)
Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, Kattan MW (2010) Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 21(1):128–138. doi:10.1097/EDE.0b013e3181c30fb2
DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845
R Development Core Team (2011). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/
Stimson CJ, Cookson MS, Barocas DA, Clark PE, Humphrey JE, Patel SG, Smith JA Jr, Chang SS (2010) Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol 183(5):1732–1737. doi:10.1016/j.juro.2010.01.028
Canter D, Long C, Kutikov A, Plimack E, Saad I, Oblaczynski M, Zhu F, Viterbo R, Chen DY, Uzzo RG, Greenberg RE, Boorjian SA (2011) Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int 107(1):58–62. doi:10.1111/j.1464-410X.2010.09442.x
Resnick MJ, Bergey M, Magerfleisch L, Tomaszewski JE, Malkowicz SB, Guzzo TJ (2011) Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens. BJU Int 107(1):46–52. doi:10.1111/j.1464-410X.2010.09635.x
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Hu-Yang Xie and Yao Zhu contributed equally to this work.
Rights and permissions
About this article
Cite this article
Xie, HY., Zhu, Y., Yao, XD. et al. Development of a nomogram to predict non-organ-confined bladder urothelial cancer before radical cystectomy. Int Urol Nephrol 44, 1711–1719 (2012). https://doi.org/10.1007/s11255-012-0273-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-012-0273-2